NASDAQ:ALNYAlnylam Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $116.38 +4.99 (+4.48 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$111.43Now: $116.38▼$117.1150-Day Range$93.12MA: $110.83▼$133.1252-Week Range$65.81Now: $116.38▼$134.51Volume50,986 shsAverage Volume960,489 shsMarket Capitalization$13.16 billionP/E RatioN/ADividend YieldN/ABeta1.95 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.72, and is based on 14 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $134.56, Alnylam Pharmaceuticals has a potential upside of 15.6% from its current price of $116.38.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesAlnylam Pharmaceuticals has received 978 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAlnylam Pharmaceuticals has received 497 “underperform” votes. (Add your “underperform” vote.)Community SentimentAlnylam Pharmaceuticals has received 66.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,091,758.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions93.83% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to decrease by -35.04% in the coming year, from ($7.22) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlnylam Pharmaceuticals has a P/B Ratio of 9.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ALNY Previous Symbol CUSIP02043Q10 CIK1178670 Webhttp://www.alnylam.com/ Phone617-551-8200Debt Debt-to-Equity Ratio0.19 Current Ratio4.87 Quick Ratio4.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$219.75 million Price / Sales59.88 Cash FlowN/A Price / Cash FlowN/A Book Value$12.90 per share Price / Book9.02Profitability EPS (Most Recent Fiscal Year)($8.11) Net Income$-886,120,000.00 Net Margins-403.24% Return on Equity-55.82% Return on Assets-36.67%Miscellaneous Employees1,323 Outstanding Shares113,070,000Market Cap$13.16 billion Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive ALNY News and Ratings via Email Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALNY Rates by TradingView Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions How has Alnylam Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALNY shares have increased by 14.2% and is now trading at $116.38. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Alnylam Pharmaceuticals? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alnylam Pharmaceuticals. When is Alnylam Pharmaceuticals' next earnings date? Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Alnylam Pharmaceuticals. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, February, 6th. The biopharmaceutical company reported ($2.47) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.25) by $0.22. The biopharmaceutical company had revenue of $71.70 million for the quarter, compared to analyst estimates of $71.45 million. Alnylam Pharmaceuticals had a negative return on equity of 55.82% and a negative net margin of 403.24%. The company's revenue was up 241.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.82) EPS. View Alnylam Pharmaceuticals' earnings history. What price target have analysts set for ALNY? 18 analysts have issued 12-month price objectives for Alnylam Pharmaceuticals' stock. Their forecasts range from $75.00 to $200.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $134.56 in the next year. This suggests a possible upside of 15.6% from the stock's current price. View analysts' price targets for Alnylam Pharmaceuticals. What are Wall Street analysts saying about Alnylam Pharmaceuticals stock? Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock: 1. According to Zacks Investment Research, "Alnylam incurred narrower-than-expected loss and beat revenue estimates in the third quarter of 2019. Onpattro continued to gain traction. The FDA set an action date of Feb 20, 2020. It showed strong commitment toward future pipeline growth through its landmark ocular and CNS disease alliance with Regeneron. The company also aims to expand the label of Onpattro for patients with cardiomyopathy and a potential label expansion should boost sales.The company’s efforts to develop its pipeline (inclisiran and lumasiran) are impressive. The company also expects to submit an NDA for inclisiran in 2019. Although we are pleased with Alnylam’s broad and promising pipeline, heavy dependence on Onpattro for growth is a concern. Moreover, the company heavily relies on its partnerships for supporting operations.Shares have outperformed the industry." (11/19/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $135 price target. Our small/mid-cap analyst Ellie Merle today launched coverage of Ionis (IONS, N). Ionis developed Onpattro competitor Tegsedi, which is now licensed to and commercialized by Akcea (AKCA, NC). We agree that Onpattro has taken meaningful share and that near-term competition from Tegsedi will likely be limited. Here we note relevant key takes from her launch and our perspective on the TTR market. We think that the overall TTR market opportunity is large, but that increasing diagnosis and treatment rates will take time." (4/9/2019) Has Alnylam Pharmaceuticals been receiving favorable news coverage? Press coverage about ALNY stock has been trending very negative recently, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAlnylam Pharmaceuticals. Who are some of Alnylam Pharmaceuticals' key competitors? Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), NVIDIA (NVDA), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), Netflix (NFLX), Opko Health (OPK) and Micron Technology (MU). Who are Alnylam Pharmaceuticals' key executives? Alnylam Pharmaceuticals' management team includes the following people: Dr. John M. Maraganore, CEO & Exec. Director (Age 56)Mr. Barry E. Greene, Pres (Age 56)Mr. Manmeet Singh Soni, Sr. VP, CFO & Principal Accounting Officer (Age 41)Dr. Yvonne Greenstreet MBChB, MBA, Exec. VP & COO (Age 56)Dr. Akshay K. Vaishnaw, Pres of R&D (Age 56) What is Alnylam Pharmaceuticals' stock symbol? Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY." Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include IFM Investors Pty Ltd (0.01%), IBM Retirement Fund (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet. View institutional ownership trends for Alnylam Pharmaceuticals. Which institutional investors are selling Alnylam Pharmaceuticals stock? ALNY stock was sold by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC, and IFM Investors Pty Ltd. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Marsha Fanucci, Philip A Sharp, Phillip A Sharp, Steven M Paul, and Yvonne Greenstreet. View insider buying and selling activity for Alnylam Pharmaceuticals. Which institutional investors are buying Alnylam Pharmaceuticals stock? ALNY stock was purchased by a variety of institutional investors in the last quarter, including IBM Retirement Fund. View insider buying and selling activity for Alnylam Pharmaceuticals. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Alnylam Pharmaceuticals' stock price today? One share of ALNY stock can currently be purchased for approximately $116.38. How big of a company is Alnylam Pharmaceuticals? Alnylam Pharmaceuticals has a market capitalization of $13.16 billion and generates $219.75 million in revenue each year. The biopharmaceutical company earns $-886,120,000.00 in net income (profit) each year or ($8.11) on an earnings per share basis. Alnylam Pharmaceuticals employs 1,323 workers across the globe. View additional information about Alnylam Pharmaceuticals. What is Alnylam Pharmaceuticals' official website? The official website for Alnylam Pharmaceuticals is http://www.alnylam.com/. How can I contact Alnylam Pharmaceuticals? Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: How much money do you need to begin day trading?
